# A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

> **NCT04266795** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 164 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Pevonedistat
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT04266795
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-13
- **Primary completion:** 2022-09-06
- **Final completion:** 2025-10-06
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04266795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04266795, "A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04266795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*